SITC 2024 Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Donwload Press release (PDF) Donwload the Poster (PDF)
Category: Tools-Home-ImagesUne
Presentation
Transgene in a nutshell Download(PDF) Corporate Presentation Download(PDF) Universal Registration Document Download(PDF)